Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Moxifloxacin Bayer.

¹Pharmaceutical Research and Development Division, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA. john.barrett@bms.com

Current Opinion in Investigational Drugs (London, England : 2000)

|March 16, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Maternal outcomes at 3 months after planned caesarean section versus planned vaginal birth for twin pregnancies in the Twin Birth Study: a randomised controlled trial.

BJOG : an international journal of obstetrics and gynaecology·2015

Same author

Bacterial resistance.

IDrugs : the investigational drugs journal·2005

Same author

Quinolone update.

IDrugs : the investigational drugs journal·2005

Same author

Targets, targets everywhere--so where are the new antibacterial drugs?

IDrugs : the investigational drugs journal·2005

Same author

American Society of Microbiology - 100th General Meeting.

IDrugs : the investigational drugs journal·2005

Same author

Antifungal agents and efflux pump inhibitors.

IDrugs : the investigational drugs journal·2005

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Bayer launched moxifloxacin, a novel fluorinated oxoquinolone antibiotic, for bacterial infections. This antibiotic received regulatory approvals in the US and EU, with market launches occurring in 1999 and 2000.

Area of Science:

Pharmacology
Infectious Diseases
Drug Development

Background:

Moxifloxacin is a novel fluorinated oxoquinolone antibiotic developed by Bayer.
It is indicated for the treatment of bacterial infections, particularly respiratory tract infections.

Purpose of the Study:

To report the launch and market progression of moxifloxacin.
To outline the regulatory approvals and sales predictions for moxifloxacin.

Main Methods:

The abstract summarizes market launch timelines and regulatory approvals based on cited references.
Sales forecasts from Lehman Brothers are included.

Main Results:

Moxifloxacin launched in Germany in September 1999 for respiratory tract infections.

Related Experiment Videos

FDA approval was granted in December 1999, with launches in the US and EU in 1999-2000, and Japan by July 2000.

Peak annual sales were predicted at US $500 million (US) in 2005 and US $800 million (ex-US) in 2007.

Conclusions:

Moxifloxacin, a significant antibiotic, successfully entered major global markets following regulatory approvals.
The drug demonstrated strong market potential with substantial predicted sales figures.